InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Idexx Laboratories

IDXX Clue Score66
United States Fiscal year ends December CIK 0000874716 Results filed 2 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

16
Insider
Date
Role
Action
Shares
Price
Amount
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
331
$711.95
$235.65K
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
775
$711.31
$551.26K
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
1,501
$710.12
$1.07M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
1,300
$709.00
$921.70K
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
1,840
$707.84
$1.30M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
840
$707.00
$593.88K
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
240
$705.59
$169.34K
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
3,950
$703.45
$2.78M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
2,136
$702.21
$1.50M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
4,540
$701.36
$3.18M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
1,667
$700.33
$1.17M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
4,075
$699.33
$2.85M
Jonathan Jay Mazelsky
4 Nov 2026
Executive Chair of the Board
Sold after exercise
1,945
$698.26
$1.36M
Sharon E. Underberg
4 Nov 2026
EVP, GC & Corporate Secretary
Sold after exercise
1,055
$690.02
$727.97K
Sharon E. Underberg
4 Nov 2026
EVP, GC & Corporate Secretary
Sold after exercise
1,503
$689.05
$1.04M
Sharon E. Underberg
4 Nov 2026
EVP, GC & Corporate Secretary
Sold after exercise
6,348
$688.25
$4.37M
Show all 21 transactions →

What was left out

Form 4 filings counted 5
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 16
Sales at will 5
Transactions with no price 0
Shares from compensation/vesting 34,094
History held since 1 Nov 2006